Modeling and Simulation in Clinical Pharmacology and Dose Finding
暂无分享,去创建一个
L. Aarons | A. Staab | M. Maliepaard | E. Rook | C. Benson
[1] M. Danhof,et al. Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development , 2013, CPT: pharmacometrics & systems pharmacology.
[2] M. Karlsson,et al. The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.
[3] O Della Pasqua,et al. Assessing the Probability of Drug‐Induced QTc‐Interval Prolongation During Clinical Drug Development , 2011, Clinical pharmacology and therapeutics.
[4] Yaning Wang,et al. Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions , 2011, Clinical pharmacokinetics.
[5] Marc Pfister,et al. Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry , 2010, Journal of clinical pharmacology.
[6] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[7] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.